Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
ONC
$347.48
-2.40%
ONC · BeOne Medicines Ltd.
$347.48
-8.53 (-2.40%)
At close · Aug 14
Market Cap
$513.62B
Shares
1.48B
All earnings calls
Earnings call · FY2026 Q2
BeOne Medicines Ltd. Q2 FY2026 Earnings Call
BeOne Medicines Ltd. Q2 FY2026 Earnings Call
Forward guidance
5 guided metrics
Management's latest ranges and targets are included below.
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$1.71B
+29.6% YoY
Diluted EPS
$0.16
+166.7% YoY
Gross margin
89.8%
+2.3 pp YoY
Net income
$237.01M
+151.3% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 5, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total revenue
table
Full Year 2026
|
$6.6B – $6.8B | — | |
|
GAAP operating income
table
Full Year 2026
|
$1B – $1.1B | GAAP | |
|
GAAP operating expenses (combined R&D and SG&A)
table
Full Year 2026
|
$4.8B – $5B | GAAP | |
|
Non-GAAP operating income
table
Full Year 2026
|
$1.7B – $1.8B | Non-GAAP | |
|
Other income (expense)
Full Year 2026
|
$-50M – $-25M | — |
Quarter detail
How the reported period landed and where the business moved.
Company presentation
Slides
12 pages · use arrow keys or swipe to navigate
SEC filing · Item 2.02
8-K earnings release
Filed Aug 5, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 5, 2026 · complete as-filed document